Isomorphic Labs
Alphabet drug-discovery AI spinoff — the AlphaFold-3 derived foundation-model platform for protein structure prediction, ligand interaction modelling and end-to-end small-molecule design — founded in 2021 out of Google DeepMind and operating a pharma-partnership commercial model with Eli Lilly, Novartis and Johnson & Johnson on $3B+ in announced milestone economics and a $2.1B Series B in May 2026.
The Business
Isomorphic Labs is an AI-led drug-discovery platform spun out of Google DeepMind in 2021 — the maker of the AlphaFold-3 derived drug-discovery foundation-model platform and the IsoDDE proprietary drug-design platform, distributed through three main surfaces: the in-house commercial platform under partner-on-platform milestone economics (the primary commercial channel, with Eli Lilly, Novartis and Johnson & Johnson as the named pharma R&D partners), an in-house therapeutic pipeline across 17 active programs in oncology, immunology and cardiovascular indications (with first Phase 1 clinical trials guided to end-2026), and the research-and-distribution backbone from the Google DeepMind AlphaFold release lineage (AlphaFold-2, AlphaFold-3 and the AlphaFold Server hosted-API surface). The company was founded in 2021 by Demis Hassabis, who continues as CEO of Isomorphic Labs and concurrently CEO of Google DeepMind, with the AlphaFold research team and a senior leadership bench including Chief AI Officer Max Jaderberg, Chief Business Officer Miles Congreve and Chief Scientific Officer Sergei Yakneen. Isomorphic Labs raised a $2.1B Series B in May 2026, led by Thrive Capital with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating — taking cumulative external equity to ~$2.7B on top of the March 2025 $600M Series A and the 2021 Alphabet founding capitalisation. The product family covers protein structure prediction, protein-ligand interaction modelling and end-to-end small-molecule design as the canonical AlphaFold-3 derived reference platform for in silico drug discovery.
Customers and Distribution
Isomorphic Labs’ customer footprint is structurally pharma-partner-on-platform: the primary distribution channel is the in-house commercial platform under named pharma R&D partnerships with Eli Lilly (announced January 2024), Novartis (announced January 2024) and Johnson & Johnson (announced 2024) — collectively $3B+ in announced milestone economics across the Eli Lilly and Novartis deals — alongside the in-house therapeutic pipeline across 17 active programs in oncology, immunology and cardiovascular indications. The pharma-partnership milestone economics is the principal published commercial-traction signal at the AI-for-drug-discovery stage, distinct from a hosted-API or per-call revenue surface; Isomorphic Labs does not publish a stand-alone revenue figure, and the IM tracker labels the headline as “pre-commercial (AI-for-drug-discovery stage)” rather than an ARR number, with the partnership milestone economics as the closest commercial-traction signal. The research-and-distribution backbone is anchored by the AlphaFold release lineage from Google DeepMind — AlphaFold-2 and AlphaFold-3 are the canonical protein structure prediction research-and-distribution platforms in the industry, and the AlphaFold Server hosted-API surface ships from Google DeepMind under a free-tier research-access-plus-partner-tier-commercial-access model that sits adjacent to the Isomorphic Labs commercial platform rather than as part of it. We decline-to-publish a precise stand-alone revenue figure pending a primary disclosure. Headcount is press-triangulated to a multi-hundred-employee range across the London and US offices through 2024 and 2025.
Model Strategy
Isomorphic Labs is a Frontier-first AI-for-drug-discovery play with a closed-platform commercial frame layered on top of a Google DeepMind research backbone: the strategic bet is that frontier capability in protein structure prediction, protein-ligand interaction modelling and end-to-end small-molecule design — shipped through the AlphaFold-3 derived foundation-model platform and the IsoDDE proprietary drug-design platform — holds the canonical reference-platform position against horizontal frontier model labs offering biology-adjacent capability through general-purpose APIs and against the closest sibling biological-foundation-model competitors. The infrastructure backstop is Google Cloud-native compute and the AlphaFold-3 model substrate carried over from Google DeepMind, alongside the May 2026 $2.1B Series B that brought UK Sovereign AI Fund sovereign-compute alignment into the capital base and takes cumulative external equity to ~$2.7B for multi-year runway through first-in-human readouts. The commercial model is partner-on-platform milestone economics with the named pharma R&D partners (Eli Lilly, Novartis, Johnson & Johnson) rather than a hosted API at per-call pricing — Isomorphic Labs does not publish per-call API pricing, and the commercial-traction signal at this stage is the milestone-economics cadence rather than a recurring-revenue ramp. The trade-off is structural pre-commercial timing — first Phase 1 clinical trials guided to end-2026 on a 12-month slip from earlier guidance — and the regulatory exposure of the drug-discovery pathway binding directly through FDA / EMA / MHRA approvals on therapeutic candidates derived from AlphaFold-3 outputs.
At A Glance
The Numbers
Active pharma partnerships
Headcount (FTE)
Funding to date
Leadership Team
Isomorphic Labs sits inside the Alphabet group as a DeepMind-aligned drug-discovery AI spinoff with founder-CEO Demis Hassabis concurrently running Google DeepMind — the leadership concentration is unusually high for a Series B biotech AI company at this scale, with Hassabis carrying both the AlphaFold research lineage and the Isomorphic Labs commercial-platform frame. Headcount has scaled into the multi-hundred range across the London and US offices through 2024 and 2025. CFO and CTO roles have not been publicly disclosed as separate appointments at the time of writing. The May 2026 $2.1B Series B brought Thrive Capital in as new lead alongside existing Alphabet, GV, MGX, Temasek and CapitalG investors and the UK Sovereign AI Fund — UK sovereign-compute alignment that strengthens the London-headquartered positioning.
IM Framework Scoring
IM’s structured assessment of Isomorphic Labs’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| May 2026 | Series B | $2.1B | — | Thrive Capital led; Alphabet, GV, MGX, Temasek, CapitalG and UK Sovereign AI Fund participating |
| Mar 2025 | Series A | $600M | — | Thrive Capital led; Alphabet (existing) participating |
| 2021 | Founding / Alphabet capitalisation | — | — | Alphabet (NASDAQ: GOOGL) founding capitalisation; spun out of Google DeepMind |
Cumulative external equity is approximately $2.7B through the May 2026 Series B ($600M Series A + $2.1B Series B) — one of the largest Series B rounds in AI-for-biology globally — led by Thrive Capital with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating. The Series B was widely covered by named-author tech and biotech press (FierceBiotech, R&D World, TechStartups) at announcement. The March 2025 Series A of $600M was led by Thrive Capital with Alphabet existing. Isomorphic Labs was founded in 2021 as an Alphabet-capitalised spin-out of Google DeepMind; precise founding capitalisation has not been publicly disclosed. The pharma-partnership milestone economics — Eli Lilly and Novartis announced 2024 with $3B+ in combined milestone payments across the two deals, and Johnson & Johnson announced 2024 — sit alongside the equity round as the principal published commercial-traction signal.
Competitive Landscape
Isomorphic Labs' competitive set sits in three concentric rings: biological-foundation-model and AI-led drug-discovery research-and-platform plays (EvolutionaryScale as the closest pure-play biology-FM competitor on the protein-structure axis; Recursion Pharmaceuticals as the public-market AI-led drug-discovery analog on the pharma-partner-on-platform model), established computational-chemistry incumbents (Schrödinger as the public-market incumbent on physics-based simulation with a growing machine-learning layer), and adjacent generative-biology specialists (AbSci on de novo antibody design; Insitro on genetics-driven target identification). Isomorphic Labs is unusual in the set because it carries the AlphaFold research lineage directly out of Google DeepMind into a closed-platform commercial frame — the only competitor on the AlphaFold-3 derived structure-to-binding-to-design axis with the Alphabet capital base behind it — while running a pharma-partner-on-platform commercial model (Eli Lilly, Novartis, Johnson & Johnson) rather than a hosted-API or in-house pipeline as the primary commercial surface.
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| EvolutionaryScale (Acquired by Chan Zuckerberg Biohub Network (Nov 2025)) |
Frontier biological foundation-model lab — the ESM3 protein sequence-to-structure-to-function model and successor releases, founded in 2024 by the ex-Meta FAIR ESM research team. The closest pure-play competitor on the biological-foundation-model-as-platform thesis on the protein-structure axis. | Hosted EvolutionaryScale API, partial-open-research release on ESM3 weights, NVIDIA BioNeMo platform integration; CZ Biohub Network research distribution on a philanthropic-research footing. | High and asymmetric — the most direct research-lineage competitor on biological foundation models; partial-open-research release model creates structural customer-portability pressure on Isomorphic Labs' closed-platform commercial frame, but EvolutionaryScale does not have the AlphaFold ligand-interaction extension into small-molecule discovery. |
| Recursion Pharmaceuticals (NASDAQ: RXRX) |
AI-led drug-discovery platform combining high-throughput cellular imaging with machine-learning models for phenotype-driven target identification; public company since 2021 with a substantial pharma-partnership book and an in-house therapeutic pipeline. | Direct therapeutic pipeline plus named pharma partnerships (Bayer, Roche / Genentech, Sanofi); NVIDIA strategic partnership announced 2023 on compute scaling. | High — the closest public-market AI-led drug-discovery competitor on the pharma-partner-on-platform commercial model; structurally further down the commercial-revenue curve than Isomorphic Labs but on a different technical axis (cellular phenotypes vs structure prediction). |
| Schrödinger (NASDAQ: SDGX) |
Computational-chemistry platform combining physics-based molecular simulation with machine-learning models for drug discovery and materials science; public company with a substantial pharma-customer book on the software-licence model and a growing in-house therapeutic pipeline. | Direct software-licence subscriptions to pharma and biotech R&D customers; in-house therapeutic pipeline with named partnerships (Bristol Myers Squibb, Otsuka). | Medium-high — the established incumbent on computational-chemistry-for-drug-discovery; structurally larger commercial revenue base than Isomorphic Labs on the software-licence model but on a different technical axis (physics-based simulation vs AlphaFold-3 derived foundation models). |
| AbSci (NASDAQ: ABSI) |
De novo antibody-design platform combining generative-AI models with proprietary wet-lab validation infrastructure for biologics discovery; public company with named pharma partnerships and an in-house therapeutic pipeline. | Pharma-partner-on-platform model with named partners (AstraZeneca, Memorial Sloan Kettering, Almirall); in-house wet-lab validation infrastructure. | Medium — narrower (biologics / antibody design rather than small-molecule discovery) but a credible flanking risk on the generative-AI-for-biologics customer segment. |
| Insitro | Machine-learning-led drug-discovery platform combining human-genetics datasets with predictive models for target identification and patient stratification; founded by Daphne Koller with substantial venture capitalisation and named pharma partnerships. | Pharma-partner-on-platform model with named partners (Bristol Myers Squibb, Gilead); in-house therapeutic pipeline focus on liver, metabolic and neurological indications. | Medium — the closest private-market machine-learning-led drug-discovery competitor on the pharma-partner-on-platform commercial model; structurally smaller capital base than Isomorphic Labs post the May 2026 Series B and on a different technical axis (genetics-driven target identification vs structure-based foundation models). |
Pricing benchmark: Isomorphic Labs does not publish per-call API pricing — the commercial model is partner-on-platform milestone economics rather than per-call inference. The closest pricing comparables are the AlphaFold Server hosted-API surface from Google DeepMind (free-tier research access plus partner-tier commercial access) and the established computational-chemistry software-licence subscriptions from Schrödinger. Pharma-partnership milestone economics — Eli Lilly and Novartis announced 2024 with $3B+ in combined milestone payments, and Johnson & Johnson announced 2024 — are the headline published commercial-traction signal. The competitive frame is research-capability-and-pharma-partnership-cadence rather than headline per-call price.
Potential Risks
The case for Isomorphic Labs at IM Framework 7.16 rests on the AlphaFold research lineage carried over from Google DeepMind, the ~$2.7B cumulative external equity capital base through the May 2026 Series B, and the named pharma R&D partnership book with Eli Lilly, Novartis and Johnson & Johnson on $3B+ in combined milestone economics. The case against splits into five risks of differing magnitude — with the pre-commercial revenue profile and the first-in-human timeline slip the most active near-term constraint on the defensibility composite, and the regulatory exposure on the drug-discovery pathway the most structural.
Pre-commercial revenue profile and first-in-human timeline slip
Isomorphic Labs does not publish a revenue figure; the AI-for-drug-discovery stage is structurally pre-commercial outside of pharma-partnership milestone payments, and the first Phase 1 clinical trials are guided to end-2026 — a 12-month slip from earlier guidance that had pointed at end-2025. The sub-rubric score on P1d time-to-revenue stage-appropriateness was held at 5 on this evidence; the disruption composite at 6.83 is essentially priced for a credible pharma-and-biotech commercial conversion path on a longer horizon than horizontal frontier model APIs, and a further slip on first-in-human readouts would weigh on the trajectory.
Regulatory exposure binds directly through the drug-discovery pathway
Drug-discovery AI faces a distinctive regulatory environment binding directly through the FDA / EMA / MHRA drug-approval pathway on therapeutic candidates derived from AlphaFold-3 outputs and the IsoDDE proprietary platform, rather than only downstream through pharma partners. The sub-rubric score on D4c regulatory exposure was held at 4 on this evidence — structurally severe but standard for AI-led drug discovery at the pre-clinical stage. None of this is fatal to Isomorphic Labs, but collectively it caps the velocity at which the platform can ship release-by-release into the most consequential therapeutic-discovery workloads and tightens the link between platform investment and clinical-readout cadence.
Key-person concentration around CEO Demis Hassabis
Demis Hassabis is concurrently CEO of Isomorphic Labs and CEO of Google DeepMind — a leadership-concentration profile unusually high for a Series B biotech AI company at this scale, with Hassabis carrying both the AlphaFold research lineage and the Isomorphic Labs commercial-platform frame in the public-facing voice. The sub-rubric score on D4e key-person dependency was held at 5 on this evidence; DeepMind talent depth mitigates the single-point-of-failure risk on the research roadmap, but a Hassabis transition would reshape the Isomorphic Labs commercial-and-research positioning materially.
Foundation-model dependency on horizontal frontier labs and the AlphaFold release boundary
Horizontal frontier model labs (OpenAI GPT-5, Anthropic Claude Opus, Google Gemini) increasingly cover biology-adjacent workloads through general-purpose APIs and large-context-window reasoning, and the AlphaFold release boundary — what ships open from DeepMind versus what stays inside the Isomorphic Labs commercial platform — is itself a dependency on Alphabet group strategy rather than a wholly independent commercial choice. The sub-rubric score on D4a supplier diversity was held at 7 on this evidence; the May 2026 UK Sovereign AI Fund participation adds sovereign-compute optionality, but the headline compute, model substrate and research lineage all sit inside the Alphabet group.
Pharma-partnership concentration and milestone-economics cadence risk
The pharma-partnership book is concentrated around three named partners — Eli Lilly and Novartis announced 2024 with $3B+ in combined milestone economics, and Johnson & Johnson announced 2024 — with 17 active programs across oncology, immunology and cardiovascular indications. The partner-on-platform commercial model is the primary published commercial-traction signal at this stage, and a partner discontinuing a program or a delayed milestone trigger would weigh disproportionately on the commercial-traction signal absent a broader hosted-platform or in-house pipeline revenue surface. The sub-rubric score on P3c GTM maturity was upgraded to 6 on the partnership confirmation but held there pending broader commercial-traction signal beyond the three named partners.
Recent IM Coverage
- Information Matters AI Tracker May 2026.
Show recent press coverage of Isomorphic Labs
- May 2026 — Isomorphic Labs raises $2.1B Series B — Thrive Capital led; Alphabet, GV, MGX, Temasek, CapitalG and UK Sovereign AI Fund participating; one of the largest Series B rounds in AI-for-biology globally.
- May 2026 — Isomorphic Labs secures $2.1B Series B to scale AlphaFold-3 derived drug-discovery platform.
- May 2026 — Isomorphic Labs $2.1B Series B at Thrive-led pricing — cumulative external equity to ~$2.7B.
- Mar 2025 — $600M Series A — Thrive Capital led; Alphabet existing; the founding venture round outside the Alphabet capitalisation base.
- Jan 2024 — Eli Lilly and Novartis pharma R&D partnerships announced — $3B+ in combined milestone economics across the two deals; AlphaFold-3 derived drug-discovery platform commercial-traction signal.
- 2024 — AlphaFold-3 release from Google DeepMind — the research-and-distribution backbone for the Isomorphic Labs drug-discovery foundation-model platform.
- 2024 — Demis Hassabis Nobel Prize in Chemistry (co-recipient) for the AlphaFold research programme — category-defining research-and-distribution signal across the Alphabet group.
Curated feed of named-source coverage — Isomorphic Labs' own newsroom, the Google DeepMind blog on AlphaFold-3, the Nobel Prize announcement, and named-author biotech and tech press (FierceBiotech, R&D World, TechStartups). Excludes paywalled article bodies of The Information, WSJ, FT and Bloomberg (headline + free-snippet only), wire-aggregator reposts and unsourced biology-AI round-up pieces.
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue (basis-disclosure note): Isomorphic Labs is an Alphabet-segment private company and does not publish a stand-alone revenue figure; the AI-for-drug-discovery stage is structurally pre-commercial outside of pharma-partnership milestone payments, with first Phase 1 clinical trials guided to end-2026. The published commercial-traction signal is the named pharma R&D partnership book — Eli Lilly and Novartis announced January 2024 with $3B+ in combined milestone economics and Johnson & Johnson announced 2024. We decline-to-publish a precise stand-alone revenue figure pending a primary disclosure and reference the pre-commercial profile only with the caveat that pharma-partnership milestone economics is the closest published commercial-traction signal.
- Usage — active programs and platform distribution: Isomorphic Labs has publicly disclosed 17 active programs across oncology, immunology and cardiovascular indications at the May 2026 Series B announcement. The AlphaFold-3 derived foundation-model layer is distributed inside the commercial-platform frame to named pharma partners (Eli Lilly, Novartis, Johnson & Johnson) under partner-on-platform milestone economics, distinct from the AlphaFold Server hosted-API surface that ships from Google DeepMind under a research-access-plus-partner-tier-commercial-access model. Isomorphic Labs does not publish a precise platform-usage figure; we decline-to-publish a precise number pending a primary disclosure.
- Headcount (basis-disclosure note): Isomorphic Labs does not publish a precise headcount figure. Named press across the May 2026 Series B announcement and the company's London and US office footprint triangulates a multi-hundred-employee range across 2024 and 2025. We decline-to-publish a precise figure pending a primary disclosure and reference the multi-hundred range only with the caveat that it is press-triangulated, not company-disclosed. Reference: FierceBiotech Series B coverage.
- Funding to date: Cumulative external equity is approximately $2.7B through the May 2026 Series B ($600M Series A + $2.1B Series B) — led by Thrive Capital with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating — on top of the March 2025 $600M Series A (Thrive-led; Alphabet existing) and the 2021 Alphabet founding capitalisation as a spin-out of Google DeepMind. References: FierceBiotech $2.1B Series B coverage; R&D World $2.1B Series B coverage; TechStartups $2.1B Series B coverage; Isomorphic Labs Series A announcement.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
